Pharmaceuticals Manufacturer and Exporters in India

Mycomun ®



Mycomun ®

Each tablet contains

Composition

Indications

Mycophenolate is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. Mycophenolate should be used concomitantly with cyclosporine and corticosteroids.

Description

The salvage pathway of purine synthesis in lymphocytes is less active than the de novo synthesis of purines. Inosine monophosphate is converted to guanosine monophosphate by inosine monophosphate dehydrogenase. During T-cell activation, the activity of both types I and II inosine monophosphate dehydrogenase enzymes increases by tenfold. Mycophenolate mofetil is converted in the liver by ester hydrolysis to mycophenolic acid, which in turn non-competitively and reversibly inhibits types I and II inosine monophosphate dehydrogenase activity during DNA synthesis in the S phase of the cell cycle. In the salvage pathway, guanine is converted to guanine monophosphate by the enzyme hypoxanthine-guanine phosphoribosyltransferase.

Dosage

K

A dose of 1 g administered orally twice a day (daily dose of 2 g) is recommended for use in renal transplant patients or as per the physician's advice.

Presentations 10 tablets